AbbVie Completes $10.9B Acquisition of Apogee Therapeutics
AbbVie Inc.
Subscribe to track ABBV
Premium users can add ticker alerts and receive realtime notification updates.
Filing Summary
AbbVie Completes Acquisition of Apogee Therapeutics ($10.9B) • Acquisition Price: $135.11 per share in cash (~$10.9B total equity value) • Key Assets: Zumilokibart (APG777 - IL-13) for atopic dermatitis, APG273 (IL-13/TSLP) for asthma • Financial Impact: Negative adjusted diluted EPS impact of $0.14 in 2026 and ~$0.46 in 2027; accretion expected by 2032 • Guidance Reaffirmed: FY 2026 adjusted diluted EPS of $13.87–$14.07; Q3 2026 adjusted diluted EPS of $3.84–$3.88
Comprehensive Analysis
AbbVie Inc. (NYSE: ABBV) Completes Acquisition of Apogee Therapeutics, Inc.
Transaction Overview
- Acquisition Target: Apogee Therapeutics, Inc. (NASDAQ: APGE)
- Transaction Consideration: $135.11 per share in cash, representing an equity value of approximately $10.9 billion.
- Closing Status: Completed on September 3, 2026; Apogee's common stock ceased trading prior to market open.
Strategic Rationale & Pipeline Assets
- Lead Asset – Zumilokibart (APG777): A half-life extended monoclonal antibody targeting IL-13 in late-stage development for atopic dermatitis (AD), supporting quarterly or twice-yearly maintenance dosing.
- APG273: A combination therapy targeting IL-13 and thymic stromal lymphopoietin (TSLP) in clinical development for asthma.
- Broad Pipeline: Expands and deepens AbbVie's core immunology franchise into large dermatologic, respiratory, and inflammatory disease markets.
Financial Guidance & Earnings Impact
- Dilution & Accretion: Expected adjusted diluted EPS dilution of $0.14 in 2026 (partial year) and ~$0.46 in 2027; accretion anticipated starting in 2032.
- FY 2026 Outlook: Reaffirmed full-year adjusted diluted EPS guidance range of $13.87 to $14.07 (which incorporates the $0.14 dilution from the acquisition).
- Q3 2026 Outlook: Reaffirmed third-quarter adjusted diluted EPS guidance range of $3.84 to $3.88.
Get Real-Time Alerts
Join our community to receive instant notifications when high-significance filings are published
Important Disclaimer
This content is AI-generated from public SEC filings and may contain errors. It is for informational and educational purposes only and is not investment, legal, or tax advice.
The Filing Fool is not a registered investment adviser, broker-dealer, or financial planner. Nothing here is a recommendation or solicitation to buy, sell, or hold any security.
Always do your own due diligence and consult a licensed professional.